Burkina Faso vs Portugal: Share of the population living with HIV receiving antiretroviral therapy
Burkina Faso
82.0%
in 2024
Portugal
82.0%
in 2017
Burkina Faso rank
46th
Portugal rank
47th
Share of the population living with HIV receiving antiretroviral therapy over time
- Burkina Faso
- Portugal
How they compare
Burkina Faso currently reports 82.0% against 82.0% in Portugal, a difference of 0.0%.
Across all 28 years both countries report, Portugal has been ahead every year.
Burkina Faso ranks 46th and Portugal ranks 47th of 149 countries.
Portugal has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burkina Faso | Portugal | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 2.4% | 2.4% | Portugal |
| 2000s | 7.9% | 32.3% | 24.5% | Portugal |
| 2010s | 45.5% | 65.1% | 19.6% | Portugal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Burkina Faso or Portugal?
- Burkina Faso, at 82.0% against 82.0% in Portugal as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Burkina Faso and Portugal?
- 0.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Portugal?
- 28 years are reported by both, from 1990 to 2017.
- How do Burkina Faso and Portugal rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Burkina Faso ranks 46th and Portugal ranks 47th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.